Exploring the scope of [Pt2(4-FC6H4)4(μ-SEt2)2] as a precursor for new organometallic platinum(II) and platinum(IV) antitumor agents

The new compound [Pt2(4-FC6H4)4(μ-SEt2)2] (A) was prepared and fully characterized. The reactions of compound A with ligands ArCH=NCH2CH2NMe2 (Ar = 2-BrC6H4, 1a; 2,6-Cl2C6H3, 1b; 4-ClC6H4, 1c; 2-Cl,6-FC6H3, 1d) were studied under different conditions and produced platinum(II) compounds [Pt(4-FC6H4)2...

Descripción completa

Detalles Bibliográficos
Autores: Escolà Jané, Anna, Crespo Vicente, Margarita Ma., Quirante Serrano, Josefina, Cortés Giràldez, Roldàn, Jayaraman, A., Badía Palacín, Josefa, Baldomà Llavinés, Laura, Calvet Pallàs, Maria Teresa, Font Bardia, Ma. Mercedes, Cascante i Serratosa, Marta
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2014
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/165418
Acceso en línea:https://hdl.handle.net/2445/165418
Access Level:acceso abierto
Palabra clave:Química organometàl·lica
Platí
Lligands
Genètica
Medicaments antineoplàstics
Estructura molecular
Organometallic chemistry
Platinum
Ligands
Genetics
Antineoplastic agents
Molecular structure
Descripción
Sumario:The new compound [Pt2(4-FC6H4)4(μ-SEt2)2] (A) was prepared and fully characterized. The reactions of compound A with ligands ArCH=NCH2CH2NMe2 (Ar = 2-BrC6H4, 1a; 2,6-Cl2C6H3, 1b; 4-ClC6H4, 1c; 2-Cl,6-FC6H3, 1d) were studied under different conditions and produced platinum(II) compounds [Pt(4-FC6H4)2(ArCH=NCH2CH2NMe2)] (2b−2d), containing a bidentate [N,N′] ligand, as well as cyclometalated platinum(IV) or platinum(II) compounds such as [PtBr(4-FC6H4)2(C6H4CH=NCH2CH2NMe2)] (4a) or [PtCl{(3-FC6H3)(2-XC6H3)CH=NCH2CH2NMe2}] (5b: X = Cl; 5d: X = F), containing a tridentate [C,N,N′] ligand and either a five (4a) or a seven (5b, 5d) membered metallacycle. These compounds exhibit a great antiproliferative activity against non-small lung cancer cells (A549), and the best result was obtained for compound 2c (IC50 = 0.3 ± 0.1 μM). While compounds 5 alter the mobility of plasmid DNA in a similar way to cisplatin, compound 4 was less efficient in removing the supercoils from DNA. In spite of the very low IC50 value obtained for compound 2c, this compound does not interact with DNA, and it is neither an intercalator nor a topoisomerase I inhibitor.

Similares en LA Referencia